ArticlePlastic and reconstructive surgery. Global open2026
Robot-assisted Axillary Lymph Node Dissection for Axillary Lymph Node Metastasis in Breast Cancer.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current experience with robotic-assisted axillary lymph node dissection (R-ALND) is limited. Axillary lymph node dissection is essential for patients with pathological N2-3 disease, but conventional open surgery carries a risk of injury to the intercostobrachial nerve, leading to sensory deficits, pain, and reduced quality of life. R-ALND may enhance precision through minimally invasive techniques, potentially reducing complications. Patients with breast cancer who underwent R-ALND at our institution between March 2024 and March 2025 were enrolled and analyzed. The procedure used the da Vinci system, following a systematic "bottom-up, back-to-front" sequence for axillary dissection, with emphasis on preserving the intercostobrachial nerve and blood vessels. The clinical characteristics, surgical outcomes, complications, and recurrence of R-ALND were analyzed. The mean operative time was 48.16 ± 9.65 minutes, with a median blood loss of 3.00 (2.00, 5.00) mL. A median of 18.00 (13.00, 22.00) lymph nodes were dissected, of which a median of 1.00 (1.00, 4.00) was metastatic. During a mean follow-up period of 8.70 ± 3.24 months, no cases of hemorrhage, infection, seroma, lymphorrhagia, upper limb lymphedema, or recurrence occurred. R-ALND is a safe and precise technique for axillary lymph node dissection, significantly reducing perioperative complications. Its technical advantages include 3-dimensional visualization and enhanced instrument maneuverability, although further validation of long-term survival benefits is required.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.